Methods of statistical analysis of censored survival times are briefly-reviewed and illustrated by application to clinical trials data. These include estimation of the survival curve, nonparametric tests to compare several survival curves, tests for trend, and regression analysis. Extensions of the methodology are made for application to epidemiologic case-control studies. These are used to estimate relative risks for leukemia asociated with radiation exposures. A final section provides some annotated references to the recent literature.
Introduction
Censored survival data arise in a wide variety of statistical investigations. In clinical trials one measures duration of response from start of treatment until relapse or death due to disease. Observations on response time are censored for those subjects still in remission at the study's end, as they are for patients lost to followup during the course of the study. Animal carcinogenesis studies, such as used by the United States Food and Drug Administration to determine the safety offood additives, provide another example. Here the endpoint is the age at diagnosis of a particular kind of cancer, censorship being imposed by death due to other causes, natural or artificial. In tests of the reliability of airplane components, failure times are measured from the start of testing until failure of the component, with censorship imposed by the failure of other components or the necessity of analyzing the data before all items have failed. Figure 1 illustrates the results for the control group in a clinical trial designed to investigate the effects of combined chemotherapy as an adjunct to surgery and radiation in the treatment of childhood rhabdomyosarcoma (1) . The endpoint for analysis was the reappearance of tumor, whether at the site of original treatment or through distant metastasis. Children who remained disease-free at the time the *Department of Biostatistics SC-32, University of Washington, Seattle, Washington 98195. data were analyzed had censored observations. In addition to the control arm IA, there were two groups of children who received the drugs actinomycin-D (AMD) and vincristine (VCR): group IB patients were concurrently randomized with the controls, both these groups having apparently had their tumors completely resected; group IIA consisted of patients with microscopic residual disease at the margin of surgical resection.
Interim data from all three arms are presented in Table 1 . Note that the censored observations for arm IA, those in the column labeled "disease-free", are smaller in the table than they are in the figure. This is because the figure was drawn from data computed at a later point in time, when additional follow-up was available for patients who had not already died.
Analysis of such data has several goals. For each of the comparison groups one wants an estimate of the survival curve, the probability of surviving t units of time. Statistical tests are required to determine whether the observed differences between the curves are real, or are simply chance effects. If real, a method of quantifying the nature of the differences is desirable. Finally there may be available concomitant observations, including continuous measurements such as age at diagnosis, whose joint effects on survival are important to determine.
Estimation of Survival Curves
When analyzing several groups of survival times the first step is to form a series of 2 x r tables as 2  12  9  12  37  25  3  15  16  19  28  9  18  19  20  29  10  24  20  38  10  36  24  42  15  40  24  45  16  45  30  47  30  31  48  34  50  42  52  44  53  59  62 refer to the total number of subjects in the ijh group who remain "at risk", i.e., alive and under observation, just prior to time tk. The tabular entries dik and Sik denote the numbers of those who die at tk, and survive tk, respectively. Table 3 illustrates the calculation of the first three such tables for the data in Table 1 . Here r = 3 and ti = 2, t2 = 3, and t3 = 9 months. Note that the tables for increasing tk refer to a constantly diminishing population "at risk" as additional subjects die or are withdrawn (censored) from further observation.
Kaplan and Meier (2) derived the maximum likelihood nonparametric estimate of the survival curve based on censored data. This may be calculated recursively, starting from P(to) = 1, and by using the formula (1): Table 4 shows the calculation of the relapse-free survival curve from the interim data in Table 1 for treatment group IA. The corresponding curves calculated from final study data for all three treatment curves are shown in Figure 2 . Numbers above each curve at annual intervals in this figure refer to numbers of patients still at risk in each group. These are an important means of judging the stability of the estimates, which can in fact be quite unstable in the "tail" ofthe survival distribution where few subjects remain at risk.
The variance of the PL estimate may also be cal- culated recursively, starting from V{P (to)} = 0. One uses the formula (2) (2) with the understanding that it is applied se;quentially to tied observations. In large samples, P(t) is approximately normally distributed with mean equal to the true survival function P(t) and a variance estimated as shown above (2, 3) . Note that neither P (t) nor V{P (t)} will change after the last uncensored response time in each group, even though additional subjects continue to be withdrawn from observation. In this region the estimated variance often does not accurately reflect the true variability in the survival curve, which will be substantial unless large numbers of subjects remain on study.
Comparison of Survival Curves
A simple but powerful non-parametric test for the comparison of r survival curves with censored data may also be calculated from the basic data shown in Table 2 . This test exploits the fact that, under the null hypothesis of no difference in the underlying survival distributions and conditional upon fixed values for the marginal totals in each 2 x r table, the vector dk = (dlk, . . ., drk)' of observed deaths at tk has an r-dimensional hypergeometric distribution. Consequently the null expectation of the number of deaths in group i at tk is eik = E(dik) = nik (Dk,Nk) (3) i.e., the number at risk in the i-th group times the death rate for all r groups combined (see Table 3 (4) has shown that V is an appropriate large sample covariance matrix for O-E. Since YOi = ;Ei, i.e. the totals of observed and expected deaths in all r groups agree, V is singular. However, defining 0* and E* to be the first r -1 components of 0 and E, and V* to be the (r -1) x (r -1) upper left hand corner of V, a test statistic for testing equality of the r survival curves is obtained as
This is approximately distributed as chi-square on r -1 degrees of freedom under the null hypothesis.
The test Ti was first proposed for survival data by Mantel (5). Cox (6) later derived it from likelihood theory under the proportional hazards (PH) model, in which the instantaneous death rates in the r groups are assumed to be in constant ratio throughout the follow-up period (see below). Peto and Peto (7) argued that it was an asymptotically efficient test under Cox's model and named it the "log rank" test.
A conservative approximation to Ti which requires no matrix inversion is given by the familiar chi-square formula
While T2 ' Ti, in fact the two statistics will be quite close, provided that there are few ties among the uncensored survival times (i.e., most of the Dk in Table 2 are unity) and that the patterns of censorship operating in the r groups are not grossly different (8, 9) . Note that the ½ continuity correction should not be used with survival data. 
Alternate Weighting Schemes
The summary statistics 0 -E weight the observed differences dk -ek in each table in a manner which is appropriate to the PH model already mentioned. However this is not the only possible weighting scheme. Multiplying the observed differences by Nk, the total number of subjects in the k-th table, and then summing, gives more weight to the earlier times tk when larger numbers are at risk. This leads to the scores and test statistic T3 = W*'Vw*-lW* (7) (8) (9) where asterisks (*) denote the corresponding r -1 dimensional quantities. A conservative approximation to T3 not requiring matrix inversion is Environmental Health Perspectives
( 1 1) The scores Wi may also be obtained from a pairwise comparison of the observations in the i-th treatment group with those in the remaining r -1 groups. Each such pair is assigned the value + I (or -1) according as the true survival time for the first pair member is known to be smaller than (or larger than) that for the second member. Ties or indeterminate comparisons due to censorship are assigned 0 values. Gehan (11) suggested the use of such scores for the comparison of two samples (r = 2). In this case T4 reduces to the familiar Wilcoxon rank sum test in the absence of ties and censorship. Breslow (12) In practice, the tests Ti and T3 often yield rather similar numerical values (see Table 5 ). However, this is not always true, and some comment on the proper interpretation when only one statistic is significant is in order. Since T3 weights early values more heavily, it may achieve significance when there is an early separation between the survival curves which later come together or even cross over. Ti gives more weight to the later appearing deaths. A large discrepancy between Ti and T3 generally indicates an interaction between treatment and time on the instantaneous death rates, which is worthy of investigation in its own right.
Testing for Trend
Often the r comparison groups correspond to r levelsxl <X2 < . . . Xr of a quantitative variable such as dose. Global chi-square tests such as Ti through T4 lack statistical power in such situations since they take no account of the natural order of the groups. One needs a single degree of freedom test for trend in survival with increasing dose.
Fortunately such a test is readily calculated from the summary statistics already at hand. In the case of the log rank analysis
Vx is a single degree of freedom chi-square for a linear trend of O-E withx. Tarone (13) has suggested using T6 = Ti -T5 as a chi-square on r-2 degrees of freedom for deviations from linearity. An approximation to T5 which only requires calculation of the 0 and E vectors is given by
Similarly, when using the W scores,
provides a test for linear trend and T9 = T3 -T7 a test for deviations from linearity.
To illustrate these calculations by using the summary data in Table 5 , make the fictitious assumption that the three treatment groups IA, IB, and IIA correspond to dose levels xi = 0, X2 = (15) does not depend on time. Thus it is called the proportional hazards (PH) model. Several authors (4, 6, 10, [15] [16] [17] have developed the likelihood analysis of the PH model from rather distinct points of view. Providing that there are no ties in the uncensored data, all derive for the lnlikelihood function of the expression (20) Notice that when ,3 = 0 this reduces to the PL estimate of Kaplan and Meier, calculated from the entire set of observations considered as one homogeneous sample. Table 7 illustrates the computer fitting of the PH model to the data on 268 leukemic children. Four regression variables were considered: zi = log (WBC), Z2 = age at diagnosis (years), Z3 = Z2, and Z4 = 1 or 0, according as the patient was treated with AMD or was a control. These four variables were entered into the regression equation sequentially in order to demonstrate their effects on remission duration after adjustment for the preceding variables. A quadratic term in the age variable was required: children in the mid ranges from 2 to 6 years have a better prognosis than at either extreme. The multiplicative effect of treatment on the relapse rate is given by exp (J34) = exp (-0.220) = 0.80, which is quite comparable with the approximate value 0.78 obtained from the simpler stratified analysis. The likelihood ratio test for treatment effectiveness yields a chi-square of 2(-876.95 + 877.99) = 2.09; squaring the standardized regression coefficient gives a similar value (_1.45)2 = 2. 11. These are both even smaller than the value of 2.80 obtained after adjustment for WBC in three strata, so that the regression approach has in this case led to an even greater reduction in the statistical significance of the treatment comparison.
As a means of providing a graphical display of the fit of the model, the regression coefficients were used to calculate a prognostic score for each child using the formula S = Z1f31 + Z2f32 + Z3133 + Z4/34 (21) Each of the covariates z was first normalized by subtracting off the mean, so that a score S = 0 represents a "typical" patient. The scores were then used to divide the sample into four groups within each of which PL estimates of the remission duration were calculated. These are plotted in Figure 3 together with predicted remission duration curves, estimated from the model, for specified values ofS. Notice that the predicted curves lie further apart than do the "observed" curves for later days, while the reverse is true for earlier days. This behavior indicates a certain lack of fit of the model, namely that the baseline covariates have more of an effect on early rates of relapse than they do on later ones. The fit could be improved by use of time-dependent covariates z(t) as discussed by Cox (6 (18) makes the sensible recommendation that he contribute a term 71 -Pk(Z), to reflect his survival disease-free over only a part of the interval.
Cox (6) suggested the use of the linear logistic model logit Pk(Z) = ak + /3'Z (23) where
This reduces to the PH model in the limit as K increases and the time or age intervals become infinitely small. The term exp (,3' z) in Eq. (23) represents the odds ratio of disease occurrence in each interval,
rather than the ratio of instantaneous failure rates.
A similar model was one of several used by Otake (19) to explore the effects of radiation on causespecific mortality using RERF data. He divided the sample into five groups according to age at the time of bomb (ATB) and six classes according to estimated total radiation doses, and considered a variety of causes of death as the endpoint. If 1950-1954, 1955-1959, etc. If nik then denotes the number of subjects who were age i ATB, received radiation dosej, and who remained alive at the midpoint of the k-th interval, the model is logit E(diJkln/Jk) = ai +/ + Yk (27) One might include also an interaction term (ay)ik so as to allow age and calendar time to have essentially arbitrary effects on disease incidence. The numbers of deaths dijk may be formally considered to have independent binomial distributions conditionally on the nik (4) .
A different approach to this problem, termed by Mantel a "synthetic retrospective study," is to draw a small sample of disease-free "controls" from each of the risk sets R(tk) for comparison with the diseased cases as they arise. The very same theory and methods may be applied also to actual case/control studies in which cases are ascertained as they occur, for example through a population based disease register. The controls, instead of being obtained from a computer file, are samples from the population in which the case arose. They may be patients with different diagnoses in the same hospital, chosen from the same family or neighborhood, or simply sampled at random from the population.
While it is impossible to estimate the incidence rates Xo(t) without studying the full cohort, the PH model assumed for the prospective study implies a probability structure for the sample cases and controls which may be used to estimate the parameter,8 describing the RR associated with the covariates (20) . Specifically, suppose m = m(t) cases having covariate vectors zl, ..., Zm are diagnosed (or die) with the particular disease at age t. Suppose also that n disease-free controls with covariates Zm+i, * * * Zm+n are drawn at random from the risk set. The analysis is performed conditionally on fixed values for m, n and the combined set of n + m observed covariate vectors. Using Cox IfR(m,n) (29) where I = (I1, . . ., 'm) ranges over the set R(m,n) of This approach was taken with an RERF data file consisting of records on 7078 males who were 50+ years old ATB. Thirteen deaths from leukemia occurred (Table 8 ). For each of these a search was made to determine the risk sets of potential controls who had the same age ATB (exact year), were residing in the same city (Hiroshima or Nagasaki), and who were alive at the end of the same year in which the case died. These ranged in size from 30 to 508 individuals.
In order to illustrate the application of the case/ control methodology, a series of 1, 2, 5, 10, and 20 controls was drawn at random from each of the risk sets. Two covariates were computed from the estimated radiation dose (in rads) for each subject: zl = ln (rads + 1) and Z2 = JiaiTs. The choice of ln (rads + 1) as a covariate in the PH model, which implies there is a linear increase in ln RR with In (rads + 1), was based on two facts: the highly skewed distribution of radiation doses; and Figure 2 of Otake (19) , which shows a nonlinear increase in In RR with dose after about 200 rad. The alternate transformation Vrads was used for comparison.
Results of the matched analyses based on the dif- Test for quadratic effect Xi = 7.34 ferent numbers of controls are shown in Table 9 . Note the decrease in the estimated standard errors as additional controls are used; however the gain afforded by using twenty rather than ten controls is not great. The regression coefficients of 0.4-0.5 for ln (rads + 1) indicate that, roughly speaking, the risk of leukemia increases by about 5% for every 10% increase in radiation dose. The disparity between the relative risks fitted under the model z = ln (rads + 1) vs. those fitted by z = rads is quite noticeable, especially when one recalls that most doses fall in the 0 -200 range. In order to try to understand better why this might occur, unmatched logistic regression analyses were carried out on the data consisting of all cases and the sets of twenty controls. The estimated slopes and standard errors were similar to those obtained with the matched analysis (Table 10 ). However the intercepts, corresponding to the estimated log odds of leukemia in the sample at a dose of zero rads, differed markedly between the two models: a = -3.97 for z = ln (rads + 1) vs. a = -3.33 for z = 7rads.
Differences in the estimated relative risk between the two models were thus explained largely by the differences in the absolute risks estimated for the baseline value of the covariate.
A potential hazard of the regression modelling of relative risks is its sensitivity to the choice of scale on which the covariate is measured. Goodness of fit of the model to the data is essential for proper interpretation, and should be explored thoroughly. When both linear and quadratic covariate terms were fitted with the models above, for example, the agreement between the estimated values for a improved substantially. Moreover the fact that the quadratic term was highly significant for the /ads model, and not at all significant for the In (rads + 1) model, showed that the latter gave much better fit to these data (Table 10) .
Further Reading
Much of the above material is presented in greater detail in a review article (10) on the PH model and its applications to survival data. Some additional applications of this model to epidemiologic studies are given by Breslow et al. (21, 22) . Peto et al. (23) present a thorough discussion of its use in the design and analysis of clinical trials.
A computer program for calculating the PL estimate and all the test statistics presented in sections 2-5 above is available (24) .
Several authors have pointed out that the W scores defined do not lead to the most efficient generalization of Wilcoxon's test to censored data. They all propose essentially the same statistic as an alternate generalization (7, 25, 26) .
A comparison of the efficiencies of the test statistics using Monte Carlo techniques is made by Lee et al. (27) . Efron (17) discusses the efficiency of the likelihood function used with the PH model from a more abstract viewpoint; see also Kalbfleisch (28) .
Additional extensions of the PH regression model for use with grouped or heavily tied data are discussed by Cox (6), Kalbfleisch and Prentice (15) , Thompson (18) , and Prentice and Gloeckler (29) .
